MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety and cost. It does not offer a formal guidance, and it, therefore, does not provide any recommendations.
Five new Medtech Innovation Briefings, including MammaTyper in vitro diagnostic test for determining breast cancer subtypes (used for determining different molecular subtypes of breast cancer to decide on systemic therapy), point-of-care creatinine tests before contrast-enhanced imaging (description of 7 technologies for point-of-care creatinine tests used to measure kidney function before contrast-enhanced imaging), plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (description of 7 plasma epidermal growth factor receptor (EGFR) mutation tests, used to inform the decision to offer EGFR tyrosine kinase inhibitors EGFR‑TKIs for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults), TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (the technology used for the imaging and videoing of the external ear canal and eardrum) and next-generation sequencing panel for solid tumour cancers in children (a next-generation sequencing (NGS)-based panel, used to sequence genetic mutations in solid tumour cancers in children) have been published the first half of January.
See full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.